Cargando…
Repositioning drug strategy against Trypanosoma cruzi: lessons learned from HIV aspartyl peptidase inhibitors
Chagas disease (CD) is an old neglected problem that affects more than 6 million people through 21 endemic countries in Latin America. Despite being responsible for more than 12 thousand deaths per year, the disease disposes basically of two drugs for its treatment, the nitroimidazole benznidazole a...
Autores principales: | Sangenito, Leandro Stefano, d’Avila-Levy, Claudia Masini, Branquinha, Marta Helena, dos Santos, André Luis Souza |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Instituto Oswaldo Cruz, Ministério da Saúde
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8925306/ https://www.ncbi.nlm.nih.gov/pubmed/35293428 http://dx.doi.org/10.1590/0074-02760210386 |
Ejemplares similares
-
Docking simulation between HIV peptidase inhibitors and Trypanosoma cruzi aspartyl peptidase
por: Castilho, Vanessa V. S., et al.
Publicado: (2018) -
Lopinavir and Nelfinavir Induce the Accumulation of Crystalloid Lipid Inclusions within the Reservosomes of Trypanosoma cruzi and Inhibit Both Aspartyl-Type Peptidase and Cruzipain Activities Detected in These Crucial Organelles
por: Sangenito, Leandro S., et al.
Publicado: (2021) -
Decoding the Anti-Trypanosoma cruzi Action of HIV Peptidase Inhibitors Using Epimastigotes as a Model
por: Sangenito, Leandro S., et al.
Publicado: (2014) -
Expression and cellular localisation of Trypanosoma cruzi calpains
por: Ennes-Vidal, Vítor, et al.
Publicado: (2020) -
Cruzipain Promotes Trypanosoma cruzi Adhesion to Rhodnius prolixus Midgut
por: Uehara, Lívia Almeida, et al.
Publicado: (2012)